The trajectory of companies tied to Sildenafil's history presents a challenging investment scenario . While the initial success generated substantial gains, generic competition have significantly eroded revenue. Investing in connected pharmaceutical businesses now requires a careful assessment of patent safeguards, evolving healthcare changes, and